Santarus, Inc. , a specialty biopharmaceutical company, today announced that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration requesting approval to begin a Phase III clinical program evaluating rifamycin SV MMX in patients with travelers’ diarrhea.
Popularity: 1% [?]

